Clinical Trials on Hepatitis C, Acute in Japan

Total 337 results

Novartis

Completed

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Toray Industries, Inc

Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Chronic Hepatitis C (CHC)

Japan
Norte Study Group
Merck Sharp & Dohme LLC

Unknown

Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...

Recruiting

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)

Chronic Hepatitis C Infection

China, Japan
Bristol-Myers Squibb

Completed

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Chugai Pharmaceutical

Completed

Trial of Pegasys® in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Kyushu University

Unknown

PEG-IFN Plus Ribavirin Combination Therapy for Older Patients

Hepatitis C Virus

Japan
Japan Liver Oncology Group

Unknown

Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease (FIBROELAST)

Chronic Hepatitis B | Chronic Hepatitis C

Japan
AbbVie

Completed

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Hepatitis C Virus (HCV)

Japan
Kyoto University

Completed

Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Hepatitis C Virus-infected Cirrhosis

Japan
Kindai University

Unknown

Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography (PICTURE)

Chronic Hepatitis B | Chronic Hepatitis C

Japan
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

A Follow-up Evaluation Study of PRI-724-1101

Hepatitis C Virus-infected Cirrhosis

Japan
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Liver Cirrhosis | Chronic Hepatitis C

Japan
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Kyoto University

Completed

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Hepatitis C, Chronic

Japan
Kyushu University
Merck Sharp & Dohme LLC

Completed

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

Chronic Kidney Disease stage3 | Hepatitis C Viral

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Hepatitis C

Japan
GlaxoSmithKline

Completed

Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Hepatitis C, Chronic

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Completed

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Hepatitis C Infection

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

Hepatitis C Infection

Japan
Bristol-Myers Squibb

Completed

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C Virus Infection

Japan
Translational Research Center for Medical Innovation...
Kyoto University

Completed

Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid

Liver Cirrhosis | Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Hepatitis C

Japan
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)

Hepatitis C, Chronic

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Hepatitis C

Japan
AbbVie

Completed

Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

Chronic Hepatitis C Virus

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
AbbVie

Recruiting

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Hepatitis C Virus (HCV)

Japan
Astellas Pharma Inc
Schering-Plough

Completed

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Hepatitis C

Japan
AbbVie

Completed

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

Chronic Hepatitis C Virus

Japan
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Hepatitis C Virus Infection

Japan

3

Subscribe